MarketPulse

Complete Response Letter

44 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed FDA Setback

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.
CORTBRBRQUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Initiates Securities Investigation into Pharming Group Following FDA Rejection

Pomerantz Law Firm investigates Pharming Group after FDA rejects pediatric drug application, causing 17% stock decline. Inquiry focuses on whether regulatory risks were adequately disclosed to investors.
PHARsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Evidence Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.
CORTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Corcept Therapeutics Faces Class Action Over Relacorilant FDA Rejection

Corcept Therapeutics faces class action lawsuit over alleged misrepresentation regarding relacorilant drug. FDA rejected the application citing insufficient efficacy data; stock plummeted over 50%.
CORTsecurities fraudclass action lawsuit